Nitrogen Attached Indirectly To The Phosphorus By Acyclic Nonionic Bonding Patents (Class 558/166)
  • Patent number: 10155780
    Abstract: New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes. The present invention is in the field of molecular biology, and more particularly in the field of transfection, which utilizes new compounds and methods for the introduction of nucleic acids into eukaryotic cells.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: December 18, 2018
    Assignee: MOLECULAR TRANSFER, INC.
    Inventors: Gulilat Gebeyehu, Joel Jessee
  • Patent number: 9493492
    Abstract: A method for producing a compound represented by General Formula (1), the method including: reacting a compound represented by General Formula (3) and a compound represented by General Formula (4): where R1 and R2 each represent aliphatic group which may have substituent, or aromatic group which may have substituent (with the proviso that R1 and R2 are different groups), R3 represents aromatic group which may have substituent, and R4 represents aliphatic group which may have substituent, or aromatic group which may have substituent, where R1 and R2 each represent aliphatic group which may have substituent, or aromatic group which may have substituent (with the proviso that R1 and R2 are different groups), and R3 represents aromatic group which may have substituent, where R4 represents aliphatic group which may have substituent, or aromatic group which may have substituent.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: November 15, 2016
    Assignee: Microbial Chemistry Research Foundation
    Inventors: Masakatsu Shibasaki, Naoya Kumagai, Liang Yin, Youmei Bao
  • Publication number: 20150077104
    Abstract: Organic compounds which contain nitrogen, fluorine, and phosphorus atoms together with carbon atoms and hydrogen atoms and which can be used as a multi-element standard for 1H—, 13C—, 15N—, 19F—, and 31P nuclear magnetic resonance spectroscopy. Also, a nuclear magnetic resonance spectroscopy method, preferably a quantitative nuclear magnetic resonance spectroscopy method, using said compounds and a method for qualitatively and/or quantitatively determining an analyte using such a nuclear magnetic resonance spectroscopy method.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 19, 2015
    Inventor: Bernd Willi Karl-Heinz Diehl
  • Publication number: 20150045484
    Abstract: The present invention relates to an amino group-containing phosphate ester flame retardant which has both a phosphate group and an amine group to exhibit a good flame retarding effect while overcoming the problems with the conventional phosphor-based flame retardants not having a good flame retarding effect with respect to its added amount, and a method of preparing the same.
    Type: Application
    Filed: March 21, 2013
    Publication date: February 12, 2015
    Inventors: In Suk Yang, Jong Cheol Lee
  • Patent number: 8940907
    Abstract: The present invention relates to a process for the preparation of phosphoric esters, and to selected compounds.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: January 27, 2015
    Assignee: Merck Patent GmbH
    Inventor: Karl Heinz Gluesenkamp
  • Patent number: 8889657
    Abstract: The present invention provides phosphonate conjugates and methods of preparing the phosphonate conjugates so as to allow, for example, improved methods and compounds for modifying the surface of a nanoparticle to increase in vivo circulation times and targeted delivery performance.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: November 18, 2014
    Assignee: Mallinckrodt LLC
    Inventor: Thomas E. Rogers
  • Patent number: 8846899
    Abstract: Disclosed are saccharide and phosphocholine derivatives. The derivatives include azide and alkyne derivatives which form one end of a variable length carbon chain. The opposite end of the variable length carbon chain is covalently linked to the saccharide or phosphocholine. The saccharide may be, for instance, a maltoside. The alkyne and azide derivatives of the saccharides and phosphocholine may be reacted together to form amphiphilic molecules useful in cellular membrane studies and applications. By adjusting the length of the carbon chain, the biochemical and biophysical properties of the resultant 1,4-disubstituted 1,2,3-triazole compounds may be custom tailored for the intended application. Resultant molecules may form micelles, bicelle, lipid bilayers and other like structures useful in the isolation and purification of membrane bound or membrane associated proteins and biochemical components.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: September 30, 2014
    Assignee: Anatrace Products, LLC
    Inventors: Benjamin R. Travis, Ritesh Mittal, Lijun Huang, Liang Tang
  • Patent number: 8815833
    Abstract: A storage stable aqueous solution of amifostine at a pH of at least 10.0, in an amifostine concentration of about 50 to about 250 mg/l, which formulation is storage stable under refrigerated conditions.
    Type: Grant
    Filed: November 8, 2007
    Date of Patent: August 26, 2014
    Assignee: Seidose, LLC
    Inventor: Nageswara R. Palepu
  • Publication number: 20140235591
    Abstract: Disclosed are compounds of Formula (I) and/or a salt thereof; wherein R is —OH or —OP(O)(OH)2. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 21, 2014
    Inventors: T. G. Murali Dhar, Hai-Yun Xiao, Alaric J. Dyckman, Eric J. Chan, Marta Dabros, Daniel Richard Roberts
  • Publication number: 20140121185
    Abstract: Novel compounds and pharmaceutical compositions thereof for the treatment and/or prevention of cancer and precancerous conditions, inflammation-related disorders, pain and fever.
    Type: Application
    Filed: September 23, 2013
    Publication date: May 1, 2014
    Applicant: MEDICON PHARMACEUTICALS, INC.
    Inventor: Basil RIGAS
  • Patent number: 8569270
    Abstract: Provided are diphenyl sulfide derivatives which have excellent S1P3 antagonistic activity and are useful as drugs. Intensive studies have been made for the purpose of creating a compound having S1P3 antagonistic activity. As a result of the intensive studies, it has been found that diphenyl sulfide derivatives represented by general formula (1) have excellent S1P3 antagonistic activity. In general formula (1), R1 is a hydrogen atom or the like; R2 is an optionally substituted alkyl group having 1 to 6 carbon atoms, or the like; X is a methylene group which may be substituted with one or two fluorine atoms, or the like; Y is a hydrogen atom or the like; and Z is a halogen atom.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: October 29, 2013
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Yasushi Kohno, Kiyoshi Fujii, Momoko Taru, Keita Miyoshi
  • Patent number: 8513418
    Abstract: The present invention relates to novel substituted bicyclic methyl amine derivatives which are useful as sphingosine-1-phosphate receptors modulators and useful for treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: August 20, 2013
    Assignee: Allergan, Inc.
    Inventors: Janet A. Takeuchi, Ling Li, Wha Bin Im
  • Patent number: 8507710
    Abstract: The invention relates to pharmaceutical compositions comprising alkylphosphocholines and antimetabolite antitumor substances. The pharmaceutical compositions of the invention are useful for the treatment of benign and malignant oncoses in humans and animals. Preferred alkylphosphocholines are described by the Formula II. One such preferred alkylphosphocholine is perifosine.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: August 13, 2013
    Assignee: AEterna Zentaris GmbH
    Inventors: Jurgen Engel, Eckhard Gunther, Herbert Sindermann
  • Publication number: 20130096295
    Abstract: Disclosed are saccharide and phosphocholine derivatives. The derivatives include azide and alkyne derivatives which form one end of a variable length carbon chain. The opposite end of the variable length carbon chain is covalently linked to the saccharide or phosphocholine. The saccharide may be, for instance, a maltoside. The alkyne and azide derivatives of the saccharides and phosphocholine may be reacted together to form amphiphilic molecules useful in cellular membrane studies and applications. By adjusting the length of the carbon chain, the biochemical and biophysical properties of the resultant 1,4-disubstituted 1,2,3-triazole compounds may be custom tailored for the intended application. Resultant molecules may form micelles, bicelle, lipid bilayers and other like structures useful in the isolation and purification of membrane bound or membrane associated proteins and biochemical components.
    Type: Application
    Filed: October 12, 2011
    Publication date: April 18, 2013
    Applicant: AFFYMETRIX, INC.
    Inventors: Benjamin R. Travis, Ritesh Mittal, Lijun Huang, Liang Tang
  • Patent number: 8383605
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II. A particularly effective treatment includes administering a combination of perifosine and capecitabine.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: February 26, 2013
    Assignee: AEterna Zentaris GmbH
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann, Babette Aicher
  • Publication number: 20130004491
    Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.
    Type: Application
    Filed: March 4, 2011
    Publication date: January 3, 2013
    Inventor: Johan Frostegård
  • Publication number: 20120322768
    Abstract: Provided are compounds, compositions and methods for treating protozoan infections.
    Type: Application
    Filed: November 24, 2010
    Publication date: December 20, 2012
    Applicants: QUEEN MARY & WESTFIELD COLLEGE, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Longqin Hu, Shane R. Wilkinson, Xinghua Wu, Belinda S. Hall
  • Publication number: 20120264715
    Abstract: The present invention relates to novel substituted bicyclic methyl amine derivatives which are useful as sphingosine-1-phosphate receptors modulators and useful for treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: April 13, 2012
    Publication date: October 18, 2012
    Inventors: Janet A. Takeuchi, Ling Li, Wha Bin Im
  • Publication number: 20120225020
    Abstract: This disclosure provides choline analogs comprising the following structure: where each R1 independently is H or isotopically enriched D, R2 is a protecting group, and N is 14N or isotopically enriched 15N. This disclosure also provides methods of making choline analogs, which include performing a protection step on a betaine aldehyde to form a choline analog, and methods of using choline analogs to form hyperpolarized compounds.
    Type: Application
    Filed: February 24, 2012
    Publication date: September 6, 2012
    Inventors: Eduard Y. Chekmenev, Roman V. Shchepin
  • Publication number: 20120215006
    Abstract: The present invention relates to a process for the preparation of phosphoric esters, and to selected compounds.
    Type: Application
    Filed: October 8, 2010
    Publication date: August 23, 2012
    Applicant: MERCK PATENTS GESSELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventor: Karl Heinz Gluesenkamp
  • Publication number: 20120141513
    Abstract: This invention relates to novel compounds that are deuterated derivatives of fingolimod and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a lysophospholipid edg1 (S1P1) receptor agonist, such as fingolimod.
    Type: Application
    Filed: December 5, 2011
    Publication date: June 7, 2012
    Inventors: Julie F. Liu, Rose A. Persichetti
  • Publication number: 20120101068
    Abstract: Provided are diphenyl sulfide derivatives which have excellent S1P3 antagonistic activity and are useful as drugs. Intensive studies have been made for the purpose of creating a compound having S1P3 antagonistic activity. As a result of the intensive studies, it has been found that diphenyl sulfide derivatives represented by general formula (1) have excellent S1P3 antagonistic activity. In general formula (1), R1 is a hydrogen atom or the like; R2 is an optionally substituted alkyl group having 1 to 6 carbon atoms, or the like; X is a methylene group which may be substituted with one or two fluorine atoms, or the like; Y is a hydrogen atom or the like; and Z is a halogen atom.
    Type: Application
    Filed: July 8, 2010
    Publication date: April 26, 2012
    Inventors: Yasushi Kohno, Kiyoshi Fujii, Momoko Taru, Keita Miyoshi
  • Patent number: 8148559
    Abstract: Disclosed are processes for development and recovery of lipids from biomass. A plant or microorganism-based biomass can be developed to encourage a desired lipid profile. Following development, ecologically friendly normally gaseous fluids such as carbon dioxide can be pressurized to a supercritical state followed by rapid expansion. The fluid is first contacted with a biomass source including oil-containing microorganisms and/or agricultural products. For instance, fungi or algae can be bioconverted from another biomass sources such as canola seed or corn syrup and then contacted with the high pressure fluid. During a contact period, the fluid can diffuse into the biomass, and in particular through the cell walls of the biomass. The fluid undergoes rapid release of pressure and opens the cell structure for improved release of oil. The fluid can optionally be utilized for extraction following the explosion process. For instance, the fluid can be re-pressurized in the same vessel for extraction processes.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: April 3, 2012
    Assignee: Clemson University Research Foundation
    Inventors: Terry H. Walker, Meidui Dong, Keri B. Cantrell, Mark C. Thies
  • Publication number: 20120027812
    Abstract: The invention relates to ophthalmological implants which comprise alkylphosphocholines. Implants of this type may in particular advantageously be used for the prophylaxis of aftercataract.
    Type: Application
    Filed: February 8, 2010
    Publication date: February 2, 2012
    Inventors: Kirsten Eibl-Lindner, Anselm Kampik, Hansjörg Eibl
  • Publication number: 20110281822
    Abstract: Novel aromatic compounds which are useful as sphingosine-1-phosphate modulators and useful for treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: May 11, 2011
    Publication date: November 17, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Janet A. Takeuchi, Ken Chow, Ling Li, Xiaoxia Liu
  • Publication number: 20110236931
    Abstract: Provided is a method to identify OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts.
    Type: Application
    Filed: April 14, 2009
    Publication date: September 29, 2011
    Applicant: HUMAN BIOMOLECULAR RESEARCH INSTITUTE
    Inventors: John R. Cashman, Mary T. MacDonald
  • Publication number: 20110213061
    Abstract: The invention relates to a method for producing mono-aminofunctionalized dialkylphosphinic acids and esters and salts thereof, characterized in that a) a phosphinic acid source (I) is reacted with olefins (IV) to yield an alkylphosphonic acid, salt or ester (II) thereof in the presence of a catalyst A, b) the thus obtained alkylphosphonic acid, salt or ester (II) thereof is reacted with acetylenic compounds of formula (V) to yield a mono-functionalized dialkylphosphinic acid derivative (VI) in the presence of a catalyst B, and c) the thus obtained mono-functionalized dialkylphosphinic acid derivative (VI) is reacted with a hydrogen cyanide source to yield a mono-functionalized dialkylphosphinic acid derivative (VII) in the presence of a catalyst C, and d) the thus obtained mono-functionalized dialkylphosphinic acid derivative (VII); is reacted to yield a mono-aminofunctionalized dialkylphosphinic acid derivative (III) in the presence of a catalyst D or a reduction agent, wherein R1, R2, R3, R4, R5, R6 are the
    Type: Application
    Filed: October 6, 2009
    Publication date: September 1, 2011
    Applicant: CLARIANT FINANCE (BVI) LIMITED
    Inventors: Michael Hill, Werner Krause, Martin Sicken
  • Publication number: 20110195936
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Application
    Filed: December 23, 2010
    Publication date: August 11, 2011
    Applicant: University of Virginia Patent Foundation
    Inventors: Kevin R. Lynch, Timothy L. MacDonald
  • Publication number: 20110152218
    Abstract: The present invention provides phospholipid in a crystalline form, a method for its preparation, compositions comprising it and its use in the treatment of damaged tissue.
    Type: Application
    Filed: March 4, 2009
    Publication date: June 23, 2011
    Inventor: Derek Woodcock
  • Patent number: 7960588
    Abstract: Sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P1 receptor type are provided. The disclosed compounds include an optional phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha-substituted phosphonates, and phosphothionates.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: June 14, 2011
    Assignee: University of Virginia Patent Foundation
    Inventors: Kevin R. Lynch, Timothy L. Macdonald
  • Publication number: 20110118210
    Abstract: Compounds of formula I: wherein R1, R2, n and m are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.
    Type: Application
    Filed: January 28, 2011
    Publication date: May 19, 2011
    Inventors: Rainer ALBERT, Eric Francotte, Frédéric Zecri, Markus Zollinger
  • Publication number: 20110100915
    Abstract: The object of the present invention is to provide a packing material and a separation method that manifest excellent hydrophilic interactions. The present invention provides a packing material for hydrophilic interaction chromatography consisting of a modified support treated with the surface modifier represented by the following formula (6) or (7). (In this formula, m denotes 2-6 and n denotes 1-4. X1, X2, and X3, independent of each other, denote a methoxy group, ethoxy group, or halogen. Up to two of X1, X2, and X3 can be any of the following groups: a methyl group, ethyl group, propyl group, isopropyl group, butyl group, or isobutyl group.
    Type: Application
    Filed: June 4, 2009
    Publication date: May 5, 2011
    Applicant: SHISEIDO COMPANY, LTD.
    Inventors: Taketoshi Kanda, Yasuo Igarashi, Kenichi Sakuma, Yousuke Toujo
  • Patent number: 7893286
    Abstract: Disclosed are improved methods for the synthesis of phospholipid ether analogs and alkyl phosphocholine analogs. The methods allow greater versatility of the reactants used and greater ease in synthesizing alkyl chains of varying length while affording reaction temperatures at room temperature or below. The methods disclosed herein provide reactants and conditions using alkyl halides and organozinc reagents and do not utilize Gringard reactions thus, allowing greater ease of their separation and purity of products. The PLE compounds synthesized by the methods disclosed herein can also be used for synthesizing high specific activity phospholipid ether (PLE) analogs, for use in treatment and diagnosis of cancer.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: February 22, 2011
    Assignee: Cellectar, Inc.
    Inventors: Anatoly Pinchuk, Jamey P. Weichert, Marc Longino
  • Publication number: 20110028421
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II. A particularly effective treatment includes administering a combination of perifosine and capecitabine.
    Type: Application
    Filed: March 31, 2010
    Publication date: February 3, 2011
    Applicant: AEterna Zentaris GmbH
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann, Babette Aicher
  • Publication number: 20110021756
    Abstract: A method of manufacturing an affinity particle includes a step of reacting a particle having a reactive functional group on a surface thereof with a ligand having a functional group having a reactivity with the reactive functional group to bond the ligand to the particle, and a step of reacting the particle to which the ligand is bonded with a surface modifying agent having a functional group represented by a general formula of: (wherein each of R1, R2, and R3 is independently an alkyl group whose carbon number is 1 or more and 6 or less, m is an integer of 2 or more and 6 or less, and n is 1 or 2.) and a functional group having a reactivity with the reactive functional group to bond the surface modifying agent to the particle to which the ligand is bonded.
    Type: Application
    Filed: January 19, 2009
    Publication date: January 27, 2011
    Inventor: Katsuyuki Maeno
  • Patent number: 7875739
    Abstract: Methods and kits for decomposing organophosphorus compounds in non-aqueous media at ambient conditions are described. Insecticides, pesticides, and chemical warfare agents can be quickly decomposed to non-toxic products. The method comprises combining the organophosphorus compound with a non-aqueous solution, preferably an alcohol, comprising metal ions and at least a trace amount of alkoxide ions. In a first preferred embodiment, the metal ion is a lanthanum ion. In a second preferred embodiment, the metal ion is a transition metal.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: January 25, 2011
    Assignee: Queen's University at Kingston
    Inventors: R. Stanley Brown, Alexei A. Neverov, Josephine S. W. Tsang
  • Publication number: 20100273745
    Abstract: Polyamine, polyamine/guanidino, and polyamine/biguanide compounds are disclosed. The compounds are useful as anti-cancer and anti-parasitic treatments. The compounds are also useful as inhibitors of the enzyme lysine-specific demethylase-1.
    Type: Application
    Filed: April 20, 2010
    Publication date: October 28, 2010
    Applicants: THE JOHNS HOPKINS UNIVERSITY, WAYNE STATE UNIVERSITY
    Inventors: Patrick M. Woster, Tracey Boncher, Robert Casero
  • Patent number: 7811548
    Abstract: The invention generally relates to novel fluorescent phospholipid compounds and compositions comprising these compounds.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: October 12, 2010
    Assignee: Cellectar, Inc.
    Inventors: Anatoly Pinchuk, Jamey P. Weichert, Marc Longino, Irawati Kandela, William R. Clarke
  • Publication number: 20100240617
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Application
    Filed: February 15, 2010
    Publication date: September 23, 2010
    Inventors: Kevin R. Lynch, Timothy L. MacDonald, Kevin Guckian, Edward Yin-shiang Lin, Bin Ma
  • Publication number: 20100204183
    Abstract: The invention relates to novel and known substituted phosphonates for use in ameliorating amyloid aggregates, particularly for use in the treatment of Alzheimer's disease.
    Type: Application
    Filed: May 2, 2008
    Publication date: August 12, 2010
    Applicant: QUEEN MARY & WESTFIELD COLLEGE
    Inventors: Alice Sullivan, Adina Michael-Titus, Lesley Robson
  • Patent number: 7772340
    Abstract: A subject-matter of the invention is alkoxyamines resulting from ?-phosphorated nitroxides corresponding to the formula: in which R represents an alkyl radical having a number of carbon atoms ranging from 1 to 3, R1 represents a hydrogen atom or a residue: in which R3 represents an alkyl radical having a number of carbon atoms ranging from 1 to 20, and R2 represents a hydrogen atom, an alkyl radical having a number of carbon atoms ranging from 1 to 8, a phenyl radical, an alkali metal, such as Li, Na or K, H4N+, Bu4N+ or Bu3HN+, exhibiting a kinetic dissociation constant kd, measured at 120° C. by EPR, of greater than 0.05 s?1. These compounds can be used as initiators for the (co)polymerizations of at least one monomer which can be polymerized by the radical route.
    Type: Grant
    Filed: July 23, 2003
    Date of Patent: August 10, 2010
    Assignee: Arkema France
    Inventors: Jean-Luc Couturier, Olivier Guerret, Denis Bertin, Didier Gigmes, Sylvain Marque, Paul Tordo, Florence Chauvin, Pierre-Emmanuel Dufils
  • Patent number: 7759326
    Abstract: Aminophosphonic acid derivatives (e.g., 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonate monoester) are represented by the following general formula (1): and act as effective S1P receptor modulators while posing less side effects.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: July 20, 2010
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Yasushi Kohno, Kiyoaki Tanaka, Kazuhiko Kuriyama, Wataru Hori
  • Publication number: 20100144676
    Abstract: The invention relates to the use of oleyl phosphocholine and oleyl-phospho-(N.N.-dimethyl-N-ethyl)-ethyl-ammonium for the long-term and continuous treatment of serious illnesses, such as cancer, leishmaniasis, ehrlichiosis, multiple sclerosis and psoriasis, in addition to other indications mentioned in the application.
    Type: Application
    Filed: March 26, 2008
    Publication date: June 10, 2010
    Applicant: Max-Planck-Gesellschaft zur Foerderung Der Wissenschaften e.V.
    Inventor: Hansjörg Eibl
  • Patent number: 7687483
    Abstract: Novel phospho-derivatives of branched-chain lipophilic molecules useful for permeabilizing biological barriers and for inhibiting tumor growth are disclosed. Pharmaceutical compositions comprising phospho-derivatives of branched-chain lipophilic molecules and their uses are also disclosed.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: March 30, 2010
    Assignee: D-Pharm Ltd.
    Inventors: Alexander Kozak, Marina Vinnikova, Michael Polyak, Eliezer Beit-Yannai, Dalia Reznitsky-Cohen, Alexander Senderikhin
  • Patent number: 7683200
    Abstract: The present invention provides methods for preparing TLR-4 receptor agonist E6020: and stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: March 23, 2010
    Assignee: Eisai R & D Management Co., Ltd.
    Inventors: Francis G. Fang, James E. Foy, Lynn Hawkins, Charles Lemelin, Andre Lescarbeau, Xiang Nu, Kuo-Ming Wu
  • Publication number: 20090324704
    Abstract: The present invention relates to lipid-analogous phosphoric acid compounds and in particular phosphoric triesters, phosphoric diester amides and phosphoric diesters. These are preferably cationic phospholipids preferably having at least one free hydroxyl group.
    Type: Application
    Filed: June 25, 2007
    Publication date: December 31, 2009
    Applicant: Max-Planck-Gesellschaft zur Foerderung Der Wissenschaften e.V.
    Inventor: Hansjörg Eibl
  • Publication number: 20090321357
    Abstract: The present invention is affinity particles that are characterized by having phosphorylcholine groups represented by the following formula (1) covalently bonded onto the surface of inorganic powder and also by having ligands having specific affinity with a certain target substance covalently bonded or adsorbed onto the surface of inorganic powder. The object of the present invention is to provide an affinity separation method that uses affinity particles utilizing inexpensive inorganic particles and is capable of separating the target substance easily and with high accuracy.
    Type: Application
    Filed: June 23, 2009
    Publication date: December 31, 2009
    Applicant: Shiseido Company, Ltd.
    Inventors: Katsuyuki Maeno, Kazuyuki Miyazawa, Akira Ishikubo, Kazuhiko Ishihara
  • Publication number: 20090308248
    Abstract: An acid gas absorbent comprising a metal sulfonate, phosphonate or carboxylate of a hindered amine and a process for the selective removal Of H2S as well as other acidic components such as carbon disulfide, carbonyl sulfide and oxygen and sulfur derivatives of C1 to C4 hydrocarbons from mixtures containing such acidic components and CO2 using said absorbent.
    Type: Application
    Filed: August 1, 2006
    Publication date: December 17, 2009
    Inventors: Michael Siskin, Alan R. Katritzky, Frank Cheng-Yu Wang
  • Patent number: 7629332
    Abstract: The present invention relates to a novel nitrophenyl mustard and nitrophenylaziridine alcohols, to their corresponding phosphates, to their use as targeted cytotoxic agents; as bioreductive drugs in hypoxic tumors, and to their use in cell ablation, including gene-directed enzyme-prodrug therapy (GPEPT) and antibody-directed enzymeprodrug therapy (ADEPT), in conjunction with nitroreductase enzymes.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: December 8, 2009
    Assignee: Auckland Uniservices Limited
    Inventors: William Alexander Denny, Graham John Atwell, Shangjin Yang, William Robert Wilson, Adam Vorn Patterson, Nuala Ann Helsby
  • Patent number: 7612238
    Abstract: Compounds of formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: November 3, 2009
    Assignee: Novartis AG
    Inventors: Peter Buehlmayer, Klaus Hinterding, Carsten Spanka, Frédéric Zecri